The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran

Journal of Clinical Psychopharmacology

Volumn 28, Issue 5, 2008, Pages 518-524

  Wakeno, Masataka ^a   Kato, Masaki ^a,b   Okugawa, Gaku ^a   Fukuda, Tsuyoshi ^c   Hosoi, Yuka ^c   Takekita, Yoshiteru ^a   Yamashita, Megumi ^c   Nonen, Shinpei ^c   Azuma, Junichi ^c   Kinoshita, Toshihiko ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; MILNACIPRAN; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; ADRENERGIC RECEPTOR AFFECTING AGENT; ALPHA 2 ADRENERGIC RECEPTOR; CYCLOPROPANE DERIVATIVE; RECEPTOR, ADRENERGIC, ALPHA 2A; RECEPTOR, ADRENERGIC, ALPHA-2A; UNCLASSIFIED DRUG;

ADRA2A GENE; ADULT; ALLELE; ANALYSIS OF VARIANCE; ARTICLE; CORRELATION ANALYSIS; DEPRESSION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DYSURIA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GENE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAMILTON SCALE; HEADACHE; HEART PALPITATION; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHOSIS; RESPIRATORY TRACT DISEASE; SOMNOLENCE; STATISTICAL ANALYSIS; TREATMENT RESPONSE; XEROSTOMIA; AGED; ASIAN; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENETICS; JAPAN; MAJOR DEPRESSION; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TIME;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIDEPRESSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CYCLOPROPANES; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENE EXPRESSION REGULATION; HUMANS; JAPAN; MALE; MIDDLE AGED; PAROXETINE; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, ADRENERGIC, ALPHA-2; TIME FACTORS;

EID: 58149139155     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31818455fc     Document Type: Article

References (42)

1. Kato M, Fukuda T, Wakeno M, et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology. 2006;53:186-195.
2. Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology. 2000;23: 587-590.
3. Smeraldi E, Zanardi R, Benedetti F, et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998;3:508-511.
4. Kim DK, Lim SW, Lee S, et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport. 2000;11:215-219.
5. Yoshida K, Takahashi H, Higuchi H, et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry. 2004;161:1575-1580.
6. Kim H, Lim SW, Kim S, et al. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA. 2006;296:1609-1618.
7. Ressler KJ, Nemeroff CB. Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol Psychiatry. 1999;46: 1291-1233.
8. Serretti A, Artioli P, Lorenzi C, et al. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Neuropsychopharmacol. 2004;7: 453-460.
9. Yu YW, Tsai SJ, Liou YJ, et al. Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur Neuropsychopharmacol. 2006; 16:498-503.
10. Brede M, Nagy G, Philipp M, et al. Differential control of adrenal and sympathetic catecholamine release by alpha 2-adrenoceptor subtypes. Mol Endocrinol. 2003;17:1640-1646.
11. Philipp M, Brede M, Hein L. Physiological significance of alpha(2)- adrenergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol. 2002;283:287-295.
12. 2O PET study of the neuromodulatory effects of clonidine. Biol Psychiatry. 2001;49:317-325.
13. García-Sevilla JA, Escriba PV, Ozaita A, et al. Up-regulation of immunolabeled a2A-adrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides. JNeurochem. 1999;72:282-291.
14. Gonzalez-Maeso J, Rodriguez-Puertas R, Meana JJ, et al. Neurotrans- mitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: selective supersensitivity of alpha(2A)- adrenoceptors. Neuropsychopharmacology. 2002;7:755-767.
15. Flügge G, van Kampen M, Meyer H, et al. α2A and α2C-adrenoceptor regulation in the brain: α2A changes persist after chronic stress. Eur J Neurosci. 2003;17:917-928.
16. 2-adrenergic receptors in major depressive disorder: binding of tritiated cloni- dine before and after tricyclic antidepressant drug treatment. Arch Gen Psychiatry. 1981;38:1327-1333.
17. 2- adrenoceptor-mediated inhibition of platelet adenylate cyclase and induction of aggregation in major depression. Arch Gen Psychiatry. 1990;47:125-132.
18. Gurguis GN, Vo SP, Griffith JM, et al. Platelet alpha2A-adrenoceptor function in major depression: Gi coupling, effects of imipramine and relationship to treatment outcome. Psychiatry Res. 1999;89:73-95.
19. De Paermentier F, Mauger JM, Lowther S, et al. Brain alpha- adrenoceptors in depressed suicides. Brain Res. 1997;757:60-68.
20. Escriba PV, Ozaita A, Garcia-Sevilla JA. Increased mRNA expression of alpha2A-adrenoceptors, serotonin receptors and mu-opioid receptors in the brains of suicide victims. Neuropsychopharmacology. 2004;29: 1512-1521.
21. Meana JJ, Barturen F, Garcia-Sevilla JA. Alpha 2-adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression. Biol Psychiatry. 1992;31:471-490.
22. Schramm NL, McDonald MP, Limbird LE. The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J Neurosci. 2001;21:4875-4882.
23. Roman T, Polanczyk GV, Zeni C, et al. Further evidence of the involvement of alpha-2A-adrenergic receptor gene (ADRA2A) in inattentive dimensional scores of attention-deficit/hyperactivity disorder. Mol Psychiatry. 2006;11:8-10.
24. Schmitz M, Denardin D, Silva TL, et al. Association between alpha-2a- adrenergic receptor gene and ADHD inattentive type. Biol Psychiatry. 2006;60:1028-1033.
25. Waldman ID, Nigg JT, Gizer IR, et al. The adrenergic receptor alpha- 2A gene (ADRA2A) and neuropsychological executive functions as putative endophenotypes for childhood ADHD. Cogn Affect Behav Neurosci. 2006;6:18-30.
26. Comings DE, Gonzalez NS, Cheng Li SC, et al. A "line item" approach to the identification of genes involved in polygenic behavioral disorders: the adrenergic alpha2A (ADRA2A) gene. Am J Med Genet B Neuro- psychiatr Genet. 2003;118:110-114.
27. Park YM, Chung YC, Lee SH, et al. Weight gain associated with the alpha2a-adrenergic receptor -1,291 C/G polymorphism and olanzapine treatment. Am JMed Genet B Neuropsychiatr Genet. 2006;141:394-397.
28. Wang YC, Bai YM, Chen JY, et al. Polymorphism of the adrenergic receptor alpha 2a -1291C>G genetic variation and clozapine-induced weight gain. J Neural Transm. 2005;112:1463-1468.
29. Fraser CM, Arakawa S, McCombie WR, et al. Cloning, sequence analysis, and permanent expression of a human alpha 2-adrenergic receptor in Chinese hamster ovary cells. J Biol Chem. 1989;264:11754-11761.
30. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IVAxis I Disorders-Patient Edition (SCID-I/P Version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute; 1995.
31. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278-296.
32. Lario S, Calls J, Cases A, et al. Mspl identifies a biallelic polymorphism in the promoter region of the alpha 2A-adrenergic receptor gene. Clin Genet. 1997;51:129-130.
33. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hills-dale, NJ: Lawrence Erlbaum Associates; 1988.
34. Shinkai K, Yoshimura R, Ueda N, et al. Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. JClin Psychopharmacol. 2004;24:11-17.
35. Sechter D, Vandel P, Weiller E, et al. A comparative study of milnacip- ran and paroxetine in outpatients with major depression. JAffect Disord. 2004;83:233-236.
36. Gilmor ML, Owens MJ, Nemeroff CB. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry. 2002;159:1702-1710.
37. Ohara K, Nagai M, Tani K, et al. Polymorphism in the promoter region of the alpha 2A adrenergic receptor gene and mood disorders. Neuroreport. 1998;9:1291-1294.
38. Sequeira A, Mamdani F, Lalovic A, et al. Alpha 2A adrenergic receptor gene and suicide. Psychiatry Res. 2004;125:87-93.
39. Polanczyk G, Zeni C, Genro JP, et al. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyper- activity disorder. Arch Gen Psychiatry. 2007;64:218-224.
40. HapMap Anonymous. The international HapMap project. Nature. 2003; 426(6968):789-796.
41. Adli M, Baethge C, Heinz A, et al. Is dose escalation of antide- pressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci. 2005; 255(6):387-400.
42. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 2000;157(4 suppl):1-45.